As can be seen in Figure 6C,D, when treating colon and prostate cancer cells, cellular mRNA levels of Bcl2 decreased in response to treatment while cellular mRNA levels of Bax increased in a time-dependent manner in both cell lines. The gene discussed is BCL2; the disease is prostate carcinoma.